Dyke-Davidoff-Masson Syndrome and Hemiplegic Cerebral Palsy: Case Report

Dyke-Davidoff-Masson syndrome (DDMS) is a rare neurological condition characterized by cerebral hemiatrophy, often resulting in hemiplegic cerebral palsy, epilepsy, and cognitive impairment. It typically stems from brain injury in the fetal or early neonatal period, leading to compensatory changes in the skull and sinuses. Clinical management focuses on symptom control, particularly for seizures and motor deficits, through multidisciplinary care.

Understanding Dyke-Davidoff-Masson Syndrome Pathophysiology

Dyke-Davidoff-Masson syndrome occurs when one hemisphere of the brain fails to develop properly or undergoes atrophy early in life. According to the National Institutes of Health (NIH) and Radiopaedia, the condition is categorized into two types: congenital, which occurs during intrauterine development, and acquired, resulting from trauma, infection, or vascular occlusion in infancy.

As the brain tissue shrinks or fails to grow, the skull undergoes compensatory changes to fill the void. This leads to characteristic radiological findings, including:

• Unilateral cerebral atrophy or hypoplasia.
• Ipsilateral calvarial thickening (the skull bone thickens on the affected side).
• Hyperpneumatization of the paranasal sinuses and mastoid air cells.
• Elevation of the petrous ridge.

Clinical Presentation and Diagnosis

Patients with DDMS often present with symptoms that mimic cerebral palsy. The most common clinical signs include hemiparesis (weakness on one side of the body), which is often more severe in the upper extremities.

Seizures are a hallmark of the syndrome. Research published in the Journal of Pediatric Neurosciences indicates that epilepsy is present in the majority of patients, often manifesting as refractory seizures that require multiple anti-epileptic medications. Cognitive impairment and learning disabilities are also frequently observed, ranging from mild delays to more significant intellectual disability.

Diagnosis is typically confirmed through neuroimaging. Magnetic resonance imaging (MRI) is the gold standard, as it provides detailed visualization of the hemiatrophy and the associated compensatory skull changes that differentiate DDMS from other causes of cerebral atrophy.

Management and Long-term Outlook

There is no cure for Dyke-Davidoff-Masson syndrome, as the underlying brain injury is permanent. Treatment is strictly symptomatic and supportive.

According to clinical guidelines, the primary goals of management include:

• Seizure Control: Use of anti-seizure medications (ASMs) to manage epilepsy. In cases of drug-resistant epilepsy, surgical intervention may be considered.
• Physical and Occupational Therapy: Essential for managing hemiplegic cerebral palsy, these therapies help maintain muscle tone, improve range of motion, and foster independence in daily activities.
• Educational Support: Speech therapy and specialized education programs address cognitive and communication challenges.

The prognosis for individuals with DDMS varies widely based on the severity of the initial brain insult and the presence of associated neurological complications. While the structural changes are life-long, early intervention with a multidisciplinary team—including neurologists, physical therapists, and pediatricians—can significantly improve the quality of life for affected adolescents and adults.

Key Clinical Considerations

Because DDMS is rare, it is often misdiagnosed or overlooked in patients presenting with hemiplegia. A thorough assessment of the skull structure during routine brain imaging is essential for accurate identification and appropriate clinical management.